Thyroid Eye Disease

Why Metrics Matter in Thyroid Eye Disease: Exploring the Innovate TED Initiative

By MedXY 09/13/2026

This article examines the critical need for refined clinical metrics in thyroid eye disease (TED) to better evaluate new targeted therapies, highlighting the Innovate TED Initiative’s efforts to develop and validate comprehensive outcome measures.

Diabetes & Endocrinology news Ophthalmology

Satralizumab Demonstrates Promising Efficacy and Safety in Treating Thyroid Eye Disease: Insights from Phase 3 SatraGO-1 and SatraGO-2 Trials

By MedXY 09/12/2026

Phase 3 trials show satralizumab significantly improves proptosis, inflammation, and diplopia in thyroid eye disease with a favorable safety profile, marking a new therapeutic option targeting the IL-6 receptor pathway.

Diabetes & Endocrinology news Ophthalmology

Teprotumumab Versus Intravenous Glucocorticoids in Thyroid Eye Disease: Insights from a Japanese MRI Study

By MedXY 08/26/2026

This study evaluates teprotumumab's effectiveness for thyroid eye disease in Japanese patients, revealing notable improvements in orbital inflammation and proptosis compared to intravenous glucocorticoid therapy with distinct MRI-based anatomical effects.

Diabetes & Endocrinology news Ophthalmology

Stimulating Thyrotropin Receptor Antibodies Amplify Fibroblast Expression of TSH and IGF-1 Receptors: Insights into Thyroid Eye Disease Pathogenesis

By MedXY 07/01/2026

Stimulating TSH receptor antibodies enhance expression of TSHR and IGF-1R in fibroblasts via receptor recycling, elucidating mechanisms underlying thyroid eye disease and identifying potential therapeutic targets.

Diabetes & Endocrinology news Ophthalmology

Veligrotug Delivers Rapid, Durable Benefit in Active Thyroid Eye Disease in the Phase 3 THRIVE Trial

By MedXY 06/06/2026

In phase 3 testing, veligrotug produced rapid and clinically meaningful reductions in proptosis, diplopia, and disease activity in active thyroid eye disease, with durable benefit through 52 weeks and a favorable short-term safety profile.

Diabetes & Endocrinology news Ophthalmology

Tocilizumab Shows Promising Benefits in Glucocorticoid-Resistant Thyroid Eye Disease

By MedXY 05/13/2026

In two prospective cohorts of active, glucocorticoid-resistant thyroid eye disease, tocilizumab improved eye inflammation, proptosis, diplopia, and quality of life with acceptable safety, supporting IL-6 blockade as a promising second-line treatment.

Diabetes & Endocrinology news Ophthalmology

Teprotumumab for Thyroid Eye Disease Carries a Measurable Long-Term Dysglycemia Risk

By MedXY 05/03/2026

A large multinational cohort study found that teprotumumab use in thyroid eye disease was associated with higher risks of prediabetes, diabetes, and antidiabetes medication initiation over 5 years.

Diabetes & Endocrinology Ophthalmology Specialties

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY 10/15/2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials

By MedXY 07/31/2025

Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.